Prognostic impact of functional mitral regurgitation prior to left ventricular assist device implantation.

Functional mitral regurgitation Heart failure Left ventricular assist device Mitral leaflet tethering Mitral valve repair Right heart failure

Journal

Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113

Informations de publication

Date de publication:
25 Feb 2022
Historique:
received: 03 10 2021
accepted: 27 12 2021
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 3 3 2022
Statut: epublish

Résumé

Functional mitral regurgitation (FMR) is a common finding of advanced heart failure with detrimental effects. The prognostic impact of uncorrected FMR prior to left ventricular assist device (LVAD) implantation remains controversial. Between 2016 and 2019 77 patients underwent continuous-flow LVAD implantation at our institution. 34 patients showed FMR ≥ 2 (MR-group), whereas 43 patients showed FMR < 2 (Control-group). Data was retrospectively analyzed. Primary composite endpoint comprised freedom from death, stroke, pump-thrombosis, major bleeding and right heart failure (RHF) after 1 year. Baseline characteristics, including the severity of left and right ventricular dysfunction, and periprocedural results were comparable. The overall survival during a mean follow up of 24.9 months was 55.9% in the MR-group versus 58.1% in the Control-group (p = 0.963), whereas 1-year event-free survival was 35.3% in the MR-group compared to 44.2% in the Control-group (p = 0.404). RHF within the first postoperative year occurred more frequently in the MR-group (35.3% vs. 11.6%; p = 0.017). Furthermore, RV function was significantly reduced in comparison to baseline values in the MR-group. 12 months after surgery, 74% of patients in the MR-group were classified as NYHA III in comparison to 24% of patients in the Control-group (p < 0.001). Preoperative uncorrected FMR prior to LVAD implantation did not affect overall survival, nevertheless it was associated with an impaired RV function and increased incidence of right heart failure during follow-up. Furthermore, preoperative FMR ≥ 2 was associated with persistent symptoms of heart failure.

Sections du résumé

BACKGROUND BACKGROUND
Functional mitral regurgitation (FMR) is a common finding of advanced heart failure with detrimental effects. The prognostic impact of uncorrected FMR prior to left ventricular assist device (LVAD) implantation remains controversial.
METHODS METHODS
Between 2016 and 2019 77 patients underwent continuous-flow LVAD implantation at our institution. 34 patients showed FMR ≥ 2 (MR-group), whereas 43 patients showed FMR < 2 (Control-group). Data was retrospectively analyzed. Primary composite endpoint comprised freedom from death, stroke, pump-thrombosis, major bleeding and right heart failure (RHF) after 1 year.
RESULTS RESULTS
Baseline characteristics, including the severity of left and right ventricular dysfunction, and periprocedural results were comparable. The overall survival during a mean follow up of 24.9 months was 55.9% in the MR-group versus 58.1% in the Control-group (p = 0.963), whereas 1-year event-free survival was 35.3% in the MR-group compared to 44.2% in the Control-group (p = 0.404). RHF within the first postoperative year occurred more frequently in the MR-group (35.3% vs. 11.6%; p = 0.017). Furthermore, RV function was significantly reduced in comparison to baseline values in the MR-group. 12 months after surgery, 74% of patients in the MR-group were classified as NYHA III in comparison to 24% of patients in the Control-group (p < 0.001).
CONCLUSIONS CONCLUSIONS
Preoperative uncorrected FMR prior to LVAD implantation did not affect overall survival, nevertheless it was associated with an impaired RV function and increased incidence of right heart failure during follow-up. Furthermore, preoperative FMR ≥ 2 was associated with persistent symptoms of heart failure.

Identifiants

pubmed: 35216595
doi: 10.1186/s13019-021-01748-9
pii: 10.1186/s13019-021-01748-9
pmc: PMC8876108
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24

Informations de copyright

© 2022. The Author(s).

Références

N Engl J Med. 2001 Nov 15;345(20):1435-43
pubmed: 11794191
Eur J Heart Fail. 2012 Aug;14(8):902-8
pubmed: 22552182
ESC Heart Fail. 2021 Apr;8(2):1596-1603
pubmed: 33635573
JACC Heart Fail. 2017 Sep;5(9):652-659
pubmed: 28859754
J Heart Lung Transplant. 2020 Mar;39(3):187-219
pubmed: 31983666
J Heart Lung Transplant. 2016 Apr;35(4):413-20
pubmed: 26922277
J Heart Lung Transplant. 2013 Sep;32(9):897-904
pubmed: 23850122
Eur J Cardiothorac Surg. 2019 Nov 1;56(5):968-975
pubmed: 31005995
J Clin Med. 2021 May 24;10(11):
pubmed: 34073744
J Thorac Cardiovasc Surg. 2012 Sep;144(3):584-603; discussion 597-8
pubmed: 22795459
J Am Coll Cardiol. 2009 Aug 18;54(8):686-94
pubmed: 19679246
N Engl J Med. 2009 Dec 03;361(23):2241-51
pubmed: 19920051
J Cardiothorac Surg. 2020 May 25;15(1):113
pubmed: 32450890
J Heart Lung Transplant. 2015 May;34(5):718-23
pubmed: 25697807
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
J Am Soc Echocardiogr. 2003 Jul;16(7):777-802
pubmed: 12835667
N Engl J Med. 2007 Aug 30;357(9):885-96
pubmed: 17761592
Heart. 2011 Oct;97(20):1675-80
pubmed: 21807656
J Am Coll Cardiol. 2009 Feb 3;53(5):401-8
pubmed: 19179197
J Am Heart Assoc. 2014 Aug 07;3(4):
pubmed: 25103202
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
J Heart Lung Transplant. 2018 Jan;37(1):79-88
pubmed: 29150326
Eur J Cardiothorac Surg. 2019 Jun 1;55(Suppl 1):i17-i25
pubmed: 31106337
J Thorac Cardiovasc Surg. 2020 Mar;159(3):897-905.e4
pubmed: 31101350
Eur J Cardiothorac Surg. 2019 Oct 1;56(4):631-642
pubmed: 31535695
JACC Heart Fail. 2017 Feb;5(2):81-88
pubmed: 28017353
Eur J Cardiothorac Surg. 2019 Aug 1;56(2):230-270
pubmed: 31100109
J Card Fail. 2012 Sep;18(9):745-8
pubmed: 22939044
J Am Coll Cardiol. 2018 Jul 31;72(5):569-580
pubmed: 30056830
J Thorac Cardiovasc Surg. 2019 May;157(5):1841-1848.e1
pubmed: 31288361
Ann Thorac Surg. 2017 Sep;104(3):811-818
pubmed: 28527962
ASAIO J. 2012 Nov-Dec;58(6):574-7
pubmed: 23103696
J Mol Cell Cardiol. 2007 Sep;43(3):231-42
pubmed: 17651751
JACC Cardiovasc Imaging. 2010 Oct;3(10):1049-64
pubmed: 20947051

Auteurs

Jonas Pausch (J)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany. j.pausch@uke.de.

Oliver Bhadra (O)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Julian Mersmann (J)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Lenard Conradi (L)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Bjoern Sill (B)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Markus J Barten (MJ)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Hermann Reichenspurner (H)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Alexander M Bernhardt (AM)

Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20251, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH